Hospitals are the ones marking up drug prices, new PhRMA report says

A new analysis commissioned for PhRMA says hospitals mark up the cost of prescription drugs on average of 500%. The report also says nearly one in five hospitals marks up the price of prescription drugs by at least 700%. (Getty/jacoblund)
A screenshot of one of PhRMA's
new advertisements. (PhRMA)

The blame game over drug prices is intensifying as drug industry group Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report Wednesday about the role hospitals are playing in marking up the cost of prescriptions.

According to the report— produced by health consulting firm The Moran Company—hospitals mark up the cost of prescription drugs on average of nearly 500%. The report also says 17% of hospitals mark up the price of prescription drugs by at least 700%.

“Hospitals receive billions of dollars every year in negotiated and mandatory discounts from biopharmaceutical companies while simultaneously increasing the price of these medicines to insurers and patients,” said Stephen J. Ubl, president and chief executive officer of PhRMA in a statement. “In order to make medicines more affordable for patients, we must address the role hospital markups play in driving up medicine costs.”

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

PhRMA said average markups were likely much higher at hospitals participating in the 340B drug pricing program where medicines are acquired, on average, at a 50% discount.

Of course, policy experts have routinely said the best way to reduce high drug costs is to lower the list price of medications set by drug companies.

RELATED: Industry groups weigh in on HHS' drug price blueprint

PhRMA has sought to spread the blame, launching ad campaigns to point to the contributions of other players including health systems, insurers and PBMs in the system after it became a natural target in the Trump administration's focus on the problem of high prescription drug prices. As the Washington Post reported earlier this year, PhRMA started an industry war by seeking to explain to consumers role of pharmacy benefit managers while also calling them "middlemen" who were pocketing savings that might otherwise belong to patients.

They face an uphill battle. Healthcare costs, including drug prices, are expected weigh heavily in the upcoming midterms and a Kaiser Family Foundation poll released Wednesday found a growing share of the public who say drug companies are making too much profit is a "major reason" why healthcare costs have been rising. The same poll found a pretty even split with about 40% of the people polled said they thought Trump's strategy of publicly shaming drug companies and asking them to cut prices will be effective while about 40% believe Trump will be able to deliver on his promise to cut the cost of prescription drugs.

RELATED: In a blow to PBMs, Trump administration mulling overhaul to drug rebate safe harbor protections 

Suggested Articles

Blue Cross and Blue Shield of North Carolina and Cambia Health Solutions have jointly decided to end their talks to enter a "strategic affiliation."

The Trump administration's new rules to overhaul the Stark Law have some areas that could create major regulatory headaches.

Medicare Part D beneficiaries could see their out-of-pocket costs go up next year before they reach catastrophic coverage, a new analysis shows.